VIVEbiotech S.L. has obtained the renewal of the CIR (Credit d’Impôt Recherche) certification for 2021, 2022 and 2023.
This certification granted by the “Ministère de lʼEnseignement supérieur, de la Recherche et de lʼInnovation” reinforces our position as a provider of R&D services for the French market thanks to the important R&D activity carried out at VIVEbiotech. Our French clients will be able to obtain important tax deductions on the R&D services contracted to the company.
In addition to manufacturing clinical quality lentiviral vectors, VIVEbiotech has an R&D department and two optimization departments in which important tasks related to optimizations linked to cost-effectiveness, scalability, regulatory or quality compliance of the production process as well as to the intrinsic biological characteristics of the vectors are performed.
See CIR (Credit d’Impôt Recherche) certification.